IMRT与3D-CRT治疗头颈部鳞癌的前瞻性随机试验长期结果
这项前瞻性随机试验比较IMRT与3D-CRT在非鼻咽头颈部鳞癌中的长期疾病结局与晚期放射毒性。中位随访140个月,10年局部区域控制、无进展生存和总生存两组均无显著差异,但IMRT组≥2级晚期口干和皮下纤维化在所有时间点均显著更少。
要点
- 10年局部区域控制、无进展生存、总生存IMRT与3D-CRT无显著差异。
- IMRT组≥2级晚期口干和皮下纤维化在所有时间点均显著少于3D-CRT。
- 随访延长后可供评估晚期放射毒性的患者减少,统计效能与精确度下降。
核心结论
- 在非鼻咽头颈部鳞癌长期生存者中,IMRT较3D-CRT持续降低中重度口干和皮下纤维化发生率,且不损害疾病相关结局。
研究设计与样本
- 前瞻性随机对照试验,纳入初治、早期至中度晚期非转移性口咽、喉或下咽鳞癌(T1-T3、N0-N2b、M0)患者,随机分入IMRT或3D-CRT。
- IMRT组66Gy/30次/6周,3D-CRT组70Gy/35次/7周,均用6MV光子照射原发灶与双侧颈部淋巴结。
- 估算样本量60例,用于显示两组≥2级急性口干发生率35%的绝对差异。
主要发现
- 中位随访140个月,10年局部区域控制率73.6%(95%CI:61.2-86%)、无进展生存率45.2%(95%CI:32-58.4%)、总生存率50.3%(95%CI:37.1-63.5%)。
- 10年局部区域控制3D-CRT 79.2%(95%CI:62.2-96.2%)对IMRT 68.7%(95%CI:51.1-86.3%),p=0.39。
- 10年无进展生存3D-CRT 41.3%(95%CI:22.3-60.3%)对IMRT 48.6%(95%CI:30.6-66.6%),p=0.59。
- 10年总生存3D-CRT 44.9%(95%CI:25.7-64.1%)对IMRT 55.0%(95%CI:37-73%),p=0.49。
- IMRT组在所有时间点≥2级晚期口干和皮下纤维化的患者比例显著更少。
关键数值与推荐
- IMRT剂量66Gy/30次/6周,3D-CRT剂量70Gy/35次/7周,均为6MV光子。
- 入组条件为口咽、喉或下咽鳞癌T1-T3、N0-N2b、M0,计划原发灶与双侧颈部淋巴结全面照射。
临床怎么用
- 对于需全面照射原发灶与双侧颈部的非鼻咽头颈部鳞癌,IMRT可在不损害长期疾病结局的前提下持续减少中重度口干和皮下纤维化。
- 选择IMRT时应权衡晚期毒性获益与长期随访中毒性评估患者减少带来的统计不确定性。
局限性
- 随访延长后可供评估晚期放射毒性的患者减少,降低了统计效能与精确度。
- 样本量按60例估算,主要针对急性口干差异,长期疾病结局比较的检验效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare long-term disease-related outcomes and late radiation morbidity between intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) in head and neck squamous cell carcinoma (HNSCC) in the setting of a prospective randomized controlled trial. METHODS: Previously untreated patients with early to moderately advanced non-metastatic squamous carcinoma of the oropharynx, larynx, or hypopharynx (T1-T3, N0-N2b, M0) planned for comprehensive irradiation of primary site and bilateral neck nodes were randomly assigned to either IMRT or 3D-CRT after written informed consent. Patients were treated with 6MV photons to a total dose of 70Gy/35 fractions over 7 weeks (3D-CRT) or 66Gy/30 fractions over 6 weeks (IMRT). A sample size of 60 patients was estimated to demonstrate 35% absolute difference in the incidence of ≥grade 2 acute xerostomia between the two arms. All time-to-event outcomes were calculated from date of randomization until the defined event using the Kaplan-Meier method. RESULTS: At a median follow-up of 140 months for surviving patients, 10-year Kaplan-Meier estimates of loco-regional control (LRC); progression-free survival (PFS); and overall survival (OS) with 95% confidence interval (95%CI) were 73.6% (95%CI: 61.2-86%); 45.2% (95%CI: 32-58.4%); and 50.3% (95%CI: 37.1-63.5%) respectively. There were no significant differences in 10-year disease-related outcomes between 3D-CRT and IMRT for LRC [79.2% (95%CI: 62.2-96.2%) vs 68.7% (95%CI: 51.1-86.3%), p = 0.39]; PFS [41.3% (95%CI: 22.3-60.3%) vs 48.6% (95%CI: 30.6-66.6%), p = 0.59]; or OS [44.9% (95%CI: 25.7-64.1%) vs 55.0% (95%CI: 37-73%), p = 0.49]. Significantly lesser proportion of patients in the IMRT arm experienced ≥grade 2 late xerostomia and subcutaneous fibrosis at all time-points. However, at longer follow-up, fewer patients remained evaluable for late radiation toxicity reducing statistical power and precision. CONCLUSIONS: IMRT provides a clinically meaningful and sustained reduction in the incidence of moderate to severe xerostomia and subcutaneous fibrosis compared to 3D-CRT without compromising disease-related outcomes in long-term survivors of non-nasopharyngeal HNSCC.
引用
- Gupta T, Sinha S, Ghosh-Laskar S, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiat Oncol. 2020. PMID: 32938468. doi:10.1186/s13014-020-01666-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。